American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
-
The pharmacology, pharmacokinetics, clinical efficacy, dosage and administration, and safety of azacitidine are reviewed. ⋯ Azacitidine is the first DNA hypomethylating agent approved by FDA for the treatment of myelodysplastic syndromes and has demonstrated superior efficacy and improvements in patients' quality of life and bone marrow function over supportive care.
-
Am J Health Syst Pharm · Aug 2005
Randomized Controlled TrialHemodynamic impact of an ephedra-free multicomponent weight-loss supplement.
The effect of Metabolife Ephedra-Free on blood pressure (BP) and hemodynamics was studied. ⋯ Single doses of Metabolife Ephedra-Free did not affect BP in healthy young volunteers. SVRI did not exceed the normal range but was elevated at five hours compared with SVRI in placebo recipients.
-
Am J Health Syst Pharm · Aug 2005
Clinical and economic outcomes of pharmacist-managed aminoglycoside or vancomycin therapy.
The associations between pharmacist-managed aminoglycoside or vancomycin therapy for hospitalized Medicare patients who had diagnoses indicating probable treatment with these antibiotics and the major health care outcomes of death rate, length of stay, Medicare charges, hearing loss, and renal impairment were explored. ⋯ The presence of pharmacist-managed aminoglycoside or vancomycin therapy was associated with significant improvement in health care and economic outcomes for Medicare patients who received these drugs.